報價延遲最少15分鐘:2024/05/12 14:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.57/-0.17
|
|
企業價值
170.45M
|
| 資產負債 |
|
每股賬面淨值
-17.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/12 14:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |